UPDATED: Ex-champ Vertex dumps hep C, but shares spike on positive CF results

John Carroll

With Gilead's Sovaldi elbowing 's Incivek aside, is calling it quits on a once-ambitious R&D effort to keep a niche for itself in hepatitis C. The market, though, didn't blink, rewarding the biotech with a in its share price after Vertex cited some early success with a combination therapy for cystic fibrosis.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS